A study on hereditary angioedema (HAE) prevalence and satisfaction with prophylaxis in South Australia has been published in the World Allergy Organization Journal (2024) 17:100918 http://doi.org/10.1016/j.waojou.2024.100918 by Alexander Troelnikov, Karen Milburn, Pravin Hissaria, Thanh Thao (Adriana) Le, and William Smith. 

This study was funded by an AIFA (Allergy and Immunology Foundation of Australasia) Primary Immunodeficiency Research Grant that was awarded in 2020.

Results from the published study include:

• Identification of 35 people with HAE in South Australia, yielding a population prevalence of 1 in 52,400, in line with average established international prevalence.
• HAE was identified in 4 patients of Indigenous Australian heritage.
• Seventeen of 31 adult patients completed an additional multi-questionnaire survey, revealing overall satisfactory disease control.
• Most common prophylactic therapies were danazol, lanadelumab, and subcutaneous C1 inhibitor.
• Many patients (mostly male) with milder disease had responded well to low-dose danazol with good tolerance and have continued to use it, whereas patients with higher disease burden are now using newer therapies, and overall satisfaction with current prophylaxis is high.

To donate to support AIFA allergy and immunology research grants go to https://www.allergyimmunology.org.au/donate

To review research projects funded by AIFA grants go to https://www.allergyimmunology.org.au/projects/projects#latest

This news item was issued on 17 July 2024 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.